Literature DB >> 19169974

Serum levels of interleukin-6, interleukin-10 and C-reactive protein in relation to left ventricular function in patients with myocardial infarction treated with primary angioplasty.

Lukasz Karpiński1, Rafał Płaksej, Wojciech Kosmala, Maria Witkowska.   

Abstract

BACKGROUND: Inflammatory factors are involved in the cardiac remodelling process after myocardial infarction (MI). Pronounced and sustained activation of proinflammatory factors is believed to enhance the damage to the myocardium and leads to its dysfunction and heart failure. Anti-inflammatory factors, especially interleukin-10 (IL-10), exert a protective action by reducing excessive inflammatory reactions. AIM: To asses the relationship between serum levels of IL-6, IL-10, CRP and echocardiographic indices of myocardial function in patients with ST-elevated myocardial infarction (STEMI) treated with primary angioplasty. Prognostic value of IL-6, IL-10 and CRP levels in predicting systolic and diastolic dysfunction 6 months after MI was also assessed.
METHODS: We studied 75 patients aged 36-82 (28 women and 47 men) presenting with STEMI treated with primary angioplasty. Blood samples for assesment of IL-6, IL-10 and CRP levels were on days 3 and 7 (3d, 7d) of MI and after 6-month follow-up (6m). Echocardiographic examination was performed on day 7 and 6 months after MI during which the parameters of LV systolic (LVEF, WMSI) and diastolic function (E/A, DT, IVRT, Ep, E/Ep) were evaluated. Twenty four healthy persons served as controls.
RESULTS: Interleukin-6 and CRP levels in consecutive measurements correlated significantly inversely with LVEF (7d) and LVEF (6m). The IL-10 (7d) and IL-10 (6m) level correlated positively with LVEF (6m) (r=0.39, p=0.02; r=0.27, p=0.04). The IL-6 and CRP levels in consecutive measurements correlated significantly positively with E/A and E/Ep and inversely with IVRT, DT and Ep. The IL-10 (3d) level correlated inversely with DT (6m) (r=-0.25, p=0.04), while IL-10 (7d) level correlated positively with DT (6m) (r=0.36, p=0.004). Increased level of IL-6 (3d) and CRP (3d) was an independent prognostic factor of LV systolic (OR=1.27, p=0.02; OR=1.14, p=0.05) and diastolic dysfunction (OR=1.14, p=0.03; OR=1.05, p=0.01) 6 months after MI.
CONCLUSIONS: 1. A significant, correlations between increased IL-6, CRP level and impaired LV systolic and diastolic function indicate the possible involvement of these factors in postinfarction cardiac damage. 2. Increased level of IL-6 and CRP in the acute phase of MI is an independent predictor of LV systolic and diastolic dysfunction 6 months after MI. 3. Increased serum level of IL-10 in the acute phase of MI reflects the extension of post-infarction myocardial lesion. 4. Maintenance of increased level of IL-10 for days/months after MI seems to be prognostically beneficial.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19169974

Source DB:  PubMed          Journal:  Kardiol Pol        ISSN: 0022-9032            Impact factor:   3.108


  11 in total

1.  Functionalized scaffold-mediated interleukin 10 gene delivery significantly improves survival rates of stem cells in vivo.

Authors:  Carolyn Holladay; Karen Power; Michael Sefton; Timothy O'Brien; William M Gallagher; Abhay Pandit
Journal:  Mol Ther       Date:  2011-01-25       Impact factor: 11.454

2.  Serum concentrations of interleukin-4 and interferon-gamma in relation to severe left ventricular dysfunction in patients with acute myocardial infarction undergoing percutaneous coronary intervention.

Authors:  Janusz Szkodzinski; Bartosz Hudzik; Marcin Osuch; Wojciech Romanowski; Bozena Szygula-Jurkiewicz; Lech Polonski; Barbara Zubelewicz-Szkodzinska
Journal:  Heart Vessels       Date:  2010-12-03       Impact factor: 2.037

3.  Diagnostic markers of acute myocardial infarction.

Authors:  Sabesan Mythili; Narasimhan Malathi
Journal:  Biomed Rep       Date:  2015-07-29

4.  A signature of aberrant immune responsiveness identifies myocardial dysfunction in rheumatoid arthritis.

Authors:  John M Davis; Keith L Knutson; Michael A Strausbauch; Cynthia S Crowson; Terry M Therneau; Peter J Wettstein; Veronique L Roger; Eric L Matteson; Sherine E Gabriel
Journal:  Arthritis Rheum       Date:  2011-06

5.  Increased prevalence of diastolic dysfunction in rheumatoid arthritis.

Authors:  Kimberly P Liang; Elena Myasoedova; Cynthia S Crowson; John M Davis; Véronique L Roger; Barry L Karon; Daniel D Borgeson; Terry M Therneau; Richard J Rodeheffer; Sherine E Gabriel
Journal:  Ann Rheum Dis       Date:  2010-05-24       Impact factor: 19.103

6.  Short-term application of tocilizumab during myocardial infarction (STAT-MI).

Authors:  Matthew B Carroll; Charles Haller; Christopher Smith
Journal:  Rheumatol Int       Date:  2017-10-24       Impact factor: 2.631

7.  IL-6 signalling in patients with acute ST-elevation myocardial infarction.

Authors:  Vibeke N Ritschel; Ingebjørg Seljeflot; Harald Arnesen; Sigrun Halvorsen; Thomas Weiss; Jan Eritsland; Geir Ø Andersen
Journal:  Results Immunol       Date:  2013-12-14

8.  Circulating Levels of IL-6 Receptor and gp130 and Long-Term Clinical Outcomes in ST-Elevation Myocardial Infarction.

Authors:  Vibeke N Ritschel; Ingebjørg Seljeflot; Harald Arnesen; Sigrun Halvorsen; Jan Eritsland; Morten W Fagerland; Geir Ø Andersen
Journal:  J Am Heart Assoc       Date:  2016-06-13       Impact factor: 5.501

9.  Serum IL-6 and IL-10 concentrations in bitches with pyometra undergoing ovariohysterectomy.

Authors:  Roman Dąbrowski; Josep Pastor; Marek Szczubiał; Tomasz Piech; Mariola Bochniarz; Władysław Wawron; Asta Tvarijonaviciute
Journal:  Acta Vet Scand       Date:  2015-09-26       Impact factor: 1.695

10.  Serum iron concentration, but not hemoglobin, correlates with TIMI risk score and 6-month left ventricular performance after primary angioplasty for acute myocardial infarction.

Authors:  Ching-Hui Huang; Chia-Chu Chang; Chen-Ling Kuo; Ching-Shan Huang; Tzai-Wen Chiu; Chih-Sheng Lin; Chin-San Liu
Journal:  PLoS One       Date:  2014-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.